Search clinical trials for: E3810

Total 17 results

Teresa Helsten, MD
Clovis Oncology, Inc.

Withdrawn

Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations

Advanced Cancer

United States
Haihe Biopharma Co., Ltd.

Unknown

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Extensive-stage Small Cell Lung Cancer

China
Eisai Co., Ltd.

Completed

Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects

Gastroesophageal Reflux Disease

United States
Eisai Co., Ltd.

Completed

A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers (Study E3810)

Healthy

Japan
Clovis Oncology, Inc.

Terminated

A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Estrogen Receptor Positive | Triple Negative | HER2 | HER2 Positive | MBC | ER

United States
Eisai Co., Ltd.

Completed

A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients

Gastroesophageal Reflux Disease

Japan
Institut de Recherches Internationales Servier

Completed

Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors

Solid Tumors

Italy, France, Spain
Eisai Co., Ltd.

Completed

A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)

Functional Dyspepsia

Japan
Eisai Co., Ltd.

Completed

Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis

Refractory Reflux Esophagitis

Japan
Eisai Co., Ltd.

Completed

A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease

Non-erosive Gastroesophageal Reflux Disease

Japan
Eisai Inc.

Completed

A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets

Healthy

United States
Eisai Co., Ltd.

Completed

Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)

Gastric or Duodenal Ulcers Caused by Low-dose Aspirin

Japan
Eisai Co., Ltd.

Completed

Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)

Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin

Japan
University of California, San Francisco
Insmed Incorporated

Terminated

Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer

Prostate Cancer

United States
Clovis Oncology, Inc.
Bristol-Myers Squibb; European Network of Gynaecological Oncological Trial...

Suspended

A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

Gynecologic Cancer | Advanced Solid Tumor

United States, Belgium, Spain, Germany, Austria, Italy
pharmaand GmbH
Gilead Sciences

Terminated

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

Ovarian Cancer | Solid Tumor | Urothelial Carcinoma | Triple-negative Breast Cancer

United States
Bristol-Myers Squibb
Eli Lilly and Company; Clovis Oncology, Inc.; Exelixis

Withdrawn

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy (CheckMate 79X)

Carcinoma, Non-small Cell Lung Cancer

Netherlands, Norway, Belgium, Greece, United States, Argentina, Denmark, Mexico, Poland, Romania

3

Subscribe